The data indicate that THC and CBD can act as TLR3 and TLR4 modulating drugs in primary immune cells in vitro, and offers insight on the cellular target(s) of phytocannabinoids in targeting inflammation in the context of MS. This evidence concerns the gene TLR4 and myeloid sarcoma.